A Phase 3 interventional study of HS-20093 in Limited-stage Small-cell Lung Cancer, sponsored by Hansoh BioMedical R&D Company. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-30.
Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the efficacy, safety and tolerability of HS-20093 compared with active surveillance as consolidation therapy after chemoradiotherapy in participants with limited-stage small cell lung cancer.
This is a randomized, controlled, open-label, multi-center, phase III clinical study to evaluate the efficacy and safety of HS-20093 versus active surveillance as consolidation therapy in participants with limited-stage small cell lung cancer (LS-SCLC) who have not progressed after receiving chemoradiotherapy (CRT).
This study consists of an experimental arm and a control arm. The experimental arm will be administered HS-20093, and the control arm will only receive active surveillance. Efficacy and safety were assessed in both arms by follow-up analyses.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
This study's planned enrollment of 406 is above the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Browse Small Cell Lung Carcinoma studies →Hansoh BioMedical R&D Company is the lead sponsor of 48 studies on the registry; 43 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Received or are receiving the following treatments:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with LS-SCLC who have not progressed following CRT. Patients in this arm will be administrated HS-20093 intravenously at a dose of 8.0 mg/kg, Q3W continuously until disease progression or until other criteria for discontinuation of treatment are met.
Drug: HS-20093
Patients with LS-SCLC who have not progressed following CRT. Patients in this arm will receive active surveillance until disease progression or until other criteria for discontinuation of active surveillance are met.
Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.
Progression-free survival (PFS) According to RECIST v1.1 by Independent Review Committee (IRC)
To assess the efficacy of HS-20093 vs active surveillance in terms of PFS. PFS is defined as the time from randomization until the date of objective disease progression or death, whichever occurred first, based on IRC using RECIST v1.1.
Time frame: Approximately 6 years
Overall survival (OS)
To assess the efficacy of HS-20093 vs active surveillance in terms of OS. Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.
Time frame: Approximately 6 years
PFS at 12 Months (PFS12) or 18 Months (PFS18) According to RECIST v1.1 by IRC
PFS12 and PFS18 are defined as the progression-free survival at 12 months and 18 months from the date of randomization, respectively, based on IRC using RECIST v1.1.
Time frame: Approximately 6 years.
ORR According to RECIST v1.1 by IRC
ORR is defined as the percentage of participants with BOR of CR or PR per RECIST v1.1
Time frame: From the date of randomization until the date of disease progression or withdrawal from study, up to approximately 6 years.
DCR According to RECIST v1.1 by IRC
DCR is defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease)
Time frame: From the date of randomization until the date of disease progression or withdrawal from study, approximately 6 years.
DoR by IRC
DoR only applies to participants whose best overall response is CR or PR. The start date is the date of first documented response of CR or PR, and the end date is defined as the date of the first documented progression or death due to underlying disease.
Time frame: From the date of CR, PR until the date of disease progression or death, approximately 6 years.
PFS According to RECIST v1.1 by investigators (INVs)
PFS is defined as the time from randomization until the date of objective disease progression or death, whichever occurred first, based on INVs using RECIST v1.1
Time frame: Approximately 6 years.
PFS12 or PFS18 According to RECIST v1.1 by INVs
PFS12 and PFS18 are defined as the progression-free survival at 12 months and 18 months from the date of randomization, respectively, based on INVs using RECIST v1.1.
Time frame: Approximately 6 years.
ORR According to RECIST v1.1 by INVs
ORR is defined as the percentage of participants with BOR of CR or PR per RECIST v1.1 by INVs.
Time frame: From the randomization until the date of disease progression or withdrawal from study, up to approximately 6 years.
DCR According to RECIST v1.1 by INVs
DCR is defined as the percentage of patients who have a best overall response (CR, PR, or stable disease).
Time frame: From the randomization until the date of disease progression or withdrawal from study, up to approximately 6 years.
DoR According to RECIST v1.1 by INVs
DoR is defined as the percentage of patients who have a best overall response (CR, PR, or stable disease).
Time frame: From the date of first dose until the date of disease progression or withdrawal from study, up to approximately 6 years.
Proportion of patients alive at 24 months (OS24) or 36 months (OS36)
OS24 and OS36 are defined as the proportion of patients alive at 24 months and 36 months from the date of randomization, respectively, based on INVs using RECIST v1.1.
Time frame: Approximately 6 years.
Incidence and severity of treatment-emergent adverse events
Adverse event (assessed according to NCI CTCAE v5.0) is defined as any untoward medical occurrence in a participant without regard to possibility of causal relationship.
Time frame: From the date of first dose until 90 days after the final dose. A cycle is 21 days.
No study locations are listed for this record.
Start is estimated for Sep 2024; primary completion for Nov 2027, 38 months later.
Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 38 months is above that.
Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risvutatug rezetecan
Hansoh BioMedical R&D Company →